Biosensors Clinical Trial Program

From a DES to a BMS

Ordering Information

<table>
<thead>
<tr>
<th>Product Code</th>
<th>Stent Diameter (mm)</th>
<th>Length (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMX-2209</td>
<td>2.25</td>
<td>8, 11, 14</td>
</tr>
<tr>
<td>BMX-2509</td>
<td>2.50</td>
<td>8, 11, 14</td>
</tr>
<tr>
<td>BMX-2709</td>
<td>2.75</td>
<td>8, 11, 14</td>
</tr>
<tr>
<td>BMX-3009</td>
<td>3.00</td>
<td>8, 11, 14</td>
</tr>
<tr>
<td>BMX-3509</td>
<td>3.50</td>
<td>8, 11, 14</td>
</tr>
<tr>
<td>BMX-4009</td>
<td>4.00</td>
<td>8, 11, 14</td>
</tr>
</tbody>
</table>

Biosensors International Group, Ltd. licenses its proprietary BAP™ drug and PFA technology to Terumo Corporation (Nobori®), Carevus, Inc. (AXXESS™) and Xentis, Inc. (XTENT®).

© 2010 Biosensors International Group, Ltd. All rights reserved.

Not available for sale in the United States and certain other countries.

All cited trademarks are the property of their respective owners.

Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

BioMatrix Flex™ Drug Eluting Stent System is CE approved.

CAUTION: These restrictions these devices to sale by or on the order of a physician, indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

BioMatrix Flex, BioMatrix, Juno, BioMatrix A9 and BA9 are trademarks or registered trademarks of Biosensors International Group, Ltd. in the United States and other countries.

All cited trademarks are the property of their respective owners.

www.biosensors.com
Everolimus -57%

**Biolimus A9™**

From a DES to a BMS

From a DES to a BMS

BA9™ drug elution

PLA biodegradation and
Abluminal biodegradable coating

– More targeted drug release

No drug carrier or drug inside the stent:

– Early BMS-like endothelial coverage

– More targeted drug release

– Reduced systemic exposure

PLA biodegradation and BA9™ drug elution

Abluminal biodegradable coating

from a DES to a BMS

**Proven safety** of a DES with an abluminal biodegradable polymer

**Confirmed safety and efficacy** out to 3 years or more:

– All-Comers” population

- With an 18% reduction in MACE compared to the Cypher® Select™ stent at 3 years in LEADERS®

- With a strong trend in favor of Biolimus Flex™

**Proven efficacy** of the Biolimus A9™ drug

- Lower level of late loss achieved in the LEADERS post-hoc analysis with the Biolimus Flex™ BMS compared to the Cypher® Select™ stent

- 0.13 mm³

**Enhanced deliverability** with advanced stent design

- Improved flexibility

- Improved trackability

- Larger side branch access

**BA9™ drug / Biodegradable PLA technology demonstrates preserved vasomotion**

- No VLST in native coronary arteries

- 2.9% for Biolimus Flex™ vs 2.2% for Cypher® Select™

- Significantly lower rate

- BALANCE Cardiac Death: MI or TVR at 1 year

3 years of follow-up

1 year

- HR 0.88 [0.66 to 1.17]

p = 0.37 *

2 years

- HR 0.84 [0.65 to 1.08]

p = 0.18 *

• Due to high lipophilicity, the drug is rapidly absorbed by tissue

• Minimizes systemic exposure and reduces the drug circulating in the bloodstream

• Due to high lipophilicity, the drug is rapidly absorbed by tissue

- **Significant Cardiac Mortality Benefit**

- LEADERS post-hoc analysis

- Mortality in Complex Patients Groups

- Significantly reduced cardiac death at 2 and 3 years

- HR 0.82 [0.65 to 1.03]

p = 0.18 *

3 years

1 year

- 19.0% for Biolimus Flex™ vs 22.1% for Cypher® Select™

- HR 0.84 [0.65 to 1.09]

p = 0.18 *